타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 4개 · 임상 갱신 필요 4개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||||
|---|---|---|---|---|
Overview Program | Disitamab Vedotin (RC48) | Disitamab Vedotin Tislelizumab | Disitamab Vedotin and Toripalimab | BT8009 |
Overview Company | RemeGen | RemeGen | RemeGen | BicycleTx Limited |
Overview Modality | ADC | ADC | ADC | ANTIBODY |
Overview Target | HER2 | HER2 | HER2 | HER2 |
Overview Indication | HER2+ urothelial, gastric, breast | Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma | Muscle Invasive Bladder Cancer; HER2 Expression | Urinary Bladder Neoplasm; Triple Negative Breast Neoplasms |
Overview Phase | APPROVED | PHASE_2 | PHASE_2 | PHASE_2 |
Overview Status | ACTIVE | ACTIVE | ACTIVE | RECRUITING |
Overview Content status | Curated Core | Standard Database | Limited Data | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · structured catalog | Editorial scope · limited data | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Emerging |
Overview Approval status | Approved (flag incomplete) | Investigational | Investigational | Investigational |
Positioning Key differentiator | Novel anti-HER2 mAb with distinct epitope | — | — | — |
Positioning Known limitation | resistance mechanisms, optimize payload delivery, and minimize off-target toxicity | — | — | — |
Positioning Development positioning | 2L+ | — | — | — |
Technology Payload | MMAE | — | — | — |
Technology Linker | Cleavable | — | — | — |
MoA Mechanism | Disitamab vedotin binds a distinct HER2 epitope (different from trastuzumab), internalizes, and releases MMAE via cleavable linker, causing microtubule disruption and apoptosis. | — | — | — |
MoA Biomarker | HER2 expression (IHC); activity in HER2+ urothelial and gastric cancers. | — | — | — |
Toxicology Species | Cynomolgus monkey | — | — | — |
Toxicology Animal (cat.) | NHP | — | — | — |
Toxicology Major finding | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. | — | — | — |
Toxicology CRS | N/A | — | — | — |
Clinical Safety signal | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. | — | — | — |
Clinical Program phase | APPROVED | PHASE_2 | PHASE_2 | PHASE_2 |
Clinical Trial activity | No active/completed counts | — | — | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 4개 · 임상 갱신 필요 4개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||||
|---|---|---|---|---|
Overview Program | Disitamab Vedotin (RC48) | Disitamab Vedotin Tislelizumab | Disitamab Vedotin and Toripalimab | BT8009 |
Overview Company | RemeGen | RemeGen | RemeGen | BicycleTx Limited |
Overview Modality | ADC | ADC | ADC | ANTIBODY |
Overview Target | HER2 | HER2 | HER2 | HER2 |
Overview Indication | HER2+ urothelial, gastric, breast | Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma | Muscle Invasive Bladder Cancer; HER2 Expression | Urinary Bladder Neoplasm; Triple Negative Breast Neoplasms |
Overview Phase | APPROVED | PHASE_2 | PHASE_2 | PHASE_2 |
Overview Status | ACTIVE | ACTIVE | ACTIVE | RECRUITING |
Overview Content status | Curated Core | Standard Database | Limited Data | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · structured catalog | Editorial scope · limited data | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Emerging |
Overview Approval status | Approved (flag incomplete) | Investigational | Investigational | Investigational |
Positioning Key differentiator | Novel anti-HER2 mAb with distinct epitope | — | — | — |
Positioning Known limitation | resistance mechanisms, optimize payload delivery, and minimize off-target toxicity | — | — | — |
Positioning Development positioning | 2L+ | — | — | — |
Technology Payload | MMAE | — | — | — |
Technology Linker | Cleavable | — | — | — |
MoA Mechanism | Disitamab vedotin binds a distinct HER2 epitope (different from trastuzumab), internalizes, and releases MMAE via cleavable linker, causing microtubule disruption and apoptosis. | — | — | — |
MoA Biomarker | HER2 expression (IHC); activity in HER2+ urothelial and gastric cancers. | — | — | — |
Toxicology Species | Cynomolgus monkey | — | — | — |
Toxicology Animal (cat.) | NHP | — | — | — |
Toxicology Major finding | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. | — | — | — |
Toxicology CRS | N/A | — | — | — |
Clinical Safety signal | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. | — | — | — |
Clinical Program phase | APPROVED | PHASE_2 | PHASE_2 | PHASE_2 |
Clinical Trial activity | No active/completed counts | — | — | — |
추천 비교
추천 비교